# Berberrubine **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/berberrubine **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-03-20 **Evidence Score:** 2 / 10 **Category:** Compound **Also Known As:** 13-methyl-9,10-dimethoxy-2,3-methylenedioxy-5,6-dihydroisoquino[3,2-a]isoquinolinium, Berberine metabolite, 9-O-methyl berberrubine, Protoberberine alkaloid derivative, BBR-M, Demethyleneberberine ## Overview Berberrubine is a protoberberine alkaloid and primary metabolite of berberine, formed via demethylation at the 9-position of the berberine molecule. It interacts with P-glycoprotein efflux transporters and demonstrates enhanced lipid solubility compared to its parent compound, potentially affecting how drugs and nutrients are absorbed and excreted. ## Health Benefits • Improved lipid solubility and P-glycoprotein affinity compared to berberine, suggesting enhanced bioavailability [5][7]. • Potential to interact with P-glycoprotein, impacting drug transport and [metabolism](/ingredients/condition/weight-management) [5]. • Exhibits high efflux ratio, indicating it may influence drug absorption and excretion [5]. • Better P-glycoprotein receptor affinity suggesting potential use in modulating drug resistance [7]. • Higher hydrophobic interactions with P-glycoprotein, which may influence its pharmacokinetic profile [5]. ## Mechanism of Action Berberrubine exerts its effects primarily through high-affinity interaction with P-glycoprotein (P-gp, encoded by ABCB1), an ATP-dependent efflux transporter expressed in intestinal epithelium, the blood-brain barrier, and hepatocytes. Its enhanced lipid solubility relative to berberine facilitates passive membrane permeation, while its elevated efflux ratio suggests it is actively pumped out of cells via P-gp, influencing net bioavailability and tissue distribution. These pharmacokinetic properties position berberrubine as a modulator of drug transport rather than solely a direct receptor agonist. ## Clinical Summary Clinical research on berberrubine specifically is extremely limited, with most available data derived from in vitro cell studies and preclinical animal models rather than human trials. Bidirectional transport assays using Caco-2 cell monolayers have demonstrated high efflux ratios for berberrubine, indicating active P-glycoprotein-mediated transport dominates its intestinal handling. No published randomized controlled trials in humans have quantified therapeutic dosages, efficacy endpoints, or safety profiles for isolated berberrubine supplementation. The current evidence base is insufficient to make definitive clinical recommendations, and findings from berberine studies should not be extrapolated directly to berberrubine. ## Nutritional Profile Berberrubine is a pure bioactive alkaloid compound (C19H17NO4, molecular weight ~323.34 g/mol), not a food ingredient, and therefore has no conventional macronutrient or micronutrient profile. It is a naturally occurring metabolite and structural analog of berberine, differing by demethylation at the C-9 position (one fewer methoxy group). As a compound, it is composed entirely of its alkaloid structure with no protein, fat, carbohydrate, fiber, vitamin, or mineral content. Bioactive compound profile: Berberrubine itself is the sole active constituent at 100% concentration in isolated form. It is classified as an isoquinoline alkaloid (protoberberine subclass). Its lipophilicity (logP) is reported to be higher than berberine, enhancing membrane permeability and oral bioavailability. Bioavailability notes: Enhanced lipid solubility compared to berberine improves passive cellular uptake. Exhibits high P-glycoprotein (P-gp) efflux ratio, which may limit net intestinal absorption but also modulates tissue distribution. Metabolically derived in vivo from berberine via demethylation by gut microbiota and hepatic CYP enzymes. Plasma concentrations in pharmacokinetic studies are typically in the nanomolar-to-low micromolar range following oral berberine administration. No dietary reference values (DRIs, RDAs) exist for berberrubine as it is not classified as a nutrient. ## Dosage & Preparation No clinically studied dosage ranges or standardized forms are available due to the absence of human trials. Preclinical studies used a 10 μM concentration in transport assays. Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions Berberrubine's strong interaction with P-glycoprotein creates a significant risk of pharmacokinetic drug interactions, as P-gp modulation can alter the absorption and elimination of co-administered drugs including digoxin, cyclosporine, and certain chemotherapeutics. Because P-gp also functions at the blood-brain barrier, berberrubine may influence CNS drug penetration, raising concern when used alongside neurologically active medications. No human safety studies have established a tolerated dose, and its use during pregnancy is contraindicated based on the known uterotonic and potentially embryotoxic properties associated with protoberberine alkaloids as a class. Individuals on polypharmacy regimens, immunosuppressants, or anticoagulants should avoid berberrubine until human pharmacokinetic data are available. ## Scientific Research No human clinical trials or meta-analyses specifically on berberrubine were found. Current research is limited to preclinical models and in vitro studies, such as those described in PubMed Central article PMC6318324. ## Historical & Cultural Context There are no documented traditional or historical medicinal uses for berberrubine. It is recognized as a natural metabolite of berberine rather than a primary compound used historically. ## Synergistic Combinations Curcumin, Quercetin, Resveratrol, Green tea extract, Piperine ## Frequently Asked Questions ### What is berberrubine and how does it differ from berberine? Berberrubine is a demethylated metabolite of berberine, differing structurally by the absence of a methoxy group at the 9-position of the isoquinoline ring. This structural change increases its lipid solubility compared to berberine, which theoretically enhances passive membrane permeation, though active P-glycoprotein efflux may offset this advantage by pumping it back out of cells. ### Does berberrubine affect drug absorption or metabolism? Yes, berberrubine exhibits a high efflux ratio in Caco-2 intestinal transport models, indicating it is actively transported out of intestinal cells by P-glycoprotein (ABCB1). Because P-gp handles many pharmaceutical drugs, berberrubine may compete with or modulate the transport of medications like digoxin, HIV protease inhibitors, and certain anticancer agents, potentially raising or lowering their effective plasma concentrations. ### Is berberrubine safe to take as a supplement? There are currently no human clinical trials establishing a safe or effective dose for berberrubine as an isolated supplement. Preclinical data suggest it interacts strongly with P-glycoprotein transporters, which creates meaningful drug interaction potential. Until rigorous human safety and pharmacokinetic studies are completed, supplementation with isolated berberrubine is not recommended without medical supervision. ### What is the bioavailability of berberrubine compared to berberine? Berberrubine has greater lipid solubility than berberine, which should theoretically improve passive absorption across cell membranes. However, its high efflux ratio in transport studies suggests P-glycoprotein actively removes it from intestinal epithelial cells, potentially limiting net oral bioavailability in a manner similar to the poor bioavailability seen with berberine itself. Head-to-head human pharmacokinetic comparisons have not yet been published. ### Can berberrubine be taken during pregnancy? Berberrubine is contraindicated during pregnancy based on the established safety concerns of the broader protoberberine alkaloid class, which includes compounds with documented uterotonic and potential embryotoxic activity. No human gestational safety data exist for berberrubine specifically, and regulatory guidance universally advises avoiding uncharacterized alkaloid supplements during pregnancy and breastfeeding. Pregnant individuals should consult an obstetrician before using any berberine-related compound. ### How does berberrubine's P-glycoprotein affinity affect its effectiveness as a supplement? Berberrubine's strong affinity for P-glycoprotein transporters means it may be more efficiently transported across cell membranes and tissue barriers compared to berberine, potentially enhancing its cellular bioavailability and therapeutic effects. This improved interaction with P-glycoprotein could allow berberrubine to achieve higher intracellular concentrations, making it a more potent option for supplement users seeking berberine-like benefits. However, this same mechanism also means berberrubine may influence how other drugs are transported in the body. ### What is the typical dosage range for berberrubine supplements? There is currently limited clinical guidance on optimal berberrubine dosing for human supplements, as most research has focused on its pharmacokinetic properties rather than dose-response studies in supplement users. Since berberrubine demonstrates superior bioavailability to berberine, lower doses may be required to achieve equivalent effects, but individual supplementation protocols should be determined in consultation with a healthcare provider. Current evidence does not yet establish a standard recommended daily intake for berberrubine. ### Can berberrubine help overcome drug-resistant conditions due to P-glycoprotein efflux? Berberrubine's high efflux ratio and P-glycoprotein modulation capability suggest potential research applications in addressing drug resistance, particularly in cases where P-glycoprotein overexpression limits drug efficacy. While preclinical studies indicate this mechanism could be therapeutically valuable, clinical evidence in humans remains limited and supplement use for this purpose is not yet supported by established research. Any interest in using berberrubine for this application should be discussed with a healthcare provider as it remains primarily a research compound. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*